Search - tctmd.com

Displaying 201 - 220 of 1259

Sort: Relevancy | Date

Presentation TCT 2016

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Presenter: Neil E. Moat, John G. Webb, Eric Van Belle

October 31, 2016

Presentation TCT 2016

EFS in the USA: Challenges and Developments (An Investigators Perspective)

Presenter: Andrew Farb, Aaron V. Kaplan, Martin B. Leon

October 31, 2016

Presentation TCT 2016

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Presenter: Neil E. Moat, John G. Webb, Scott Lim

October 31, 2016

Presentation TCT 2016

2016 Treatment of Saphenous Vein Grafts, Including Management of Acute Occlusions

Presenter: Jonathan M. Hill, Dimitri Karmpaliotis, Joseph P. Carrozza Jr

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Early Feasibility Studies in the USA: Early Example With Success

Presenter: Andrew Farb, Aaron V. Kaplan, Steven R. Bailey

October 31, 2016

Presentation TCT 2016

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Presenter: Neil E. Moat, John G. Webb, Jeffrey J. Popma

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Early Feasibility Studies in USA: Progress Report From the FDA

Presenter: Andrew Farb, Aaron V. Kaplan, Carla M Wiese

October 31, 2016

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

TOTAL Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Francesco Burzotta

October 31, 2016

Presentation TCT 2016

Trial #5 - The Essentials of TOTAL - One-Year Outcomes of Aspiration in STEMI

Presenter: Sunil V. Rao, Harvey D. White, Warren J. Cantor

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Philip James Devereaux

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Manesh R. Patel

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

STICH and STICHES Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, James E. Udelson

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing I: YODA Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Harlan Krumholz

October 31, 2016

Advertisement

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

EFS in the USA: Challenges and Developments (An Investigators Perspective)

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

2016 Treatment of Saphenous Vein Grafts, Including Management of Acute Occlusions

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Early Feasibility Studies in the USA: Early Example With Success

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Early Feasibility Studies in USA: Progress Report From the FDA

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

TOTAL Critique: Pros and Cons

Trial #5 - The Essentials of TOTAL - One-Year Outcomes of Aspiration in STEMI

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

STICH and STICHES Critique: Pros and Cons

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Opportunities and Risks of Data Sharing I: YODA Proposal

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content